Free Trial

Nutex Health (NUTX) Financials

Nutex Health logo
$138.16 -6.88 (-4.74%)
As of 09:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Nutex Health

Annual Income Statements for Nutex Health

This table shows Nutex Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-425 -46 52
Consolidated Net Income / (Loss)
-433 -43 95
Net Income / (Loss) Continuing Operations
-433 -43 95
Total Pre-Tax Income
-420 -48 110
Total Operating Income
-407 -32 131
Total Gross Profit
15 35 196
Total Revenue
219 248 480
Operating Revenue
219 248 480
Total Cost of Revenue
124 123 133
Operating Cost of Revenue
124 123 133
Total Operating Expenses
502 157 217
Selling, General & Admin Expense
87 106 174
Depreciation Expense
13 18 19
Other Operating Expenses / (Income)
0.19 3.05 17
Impairment Charge
398 30 7.08
Restructuring Charge
3.89 0.04 0.00
Total Other Income / (Expense), net
-13 -17 -21
Interest Expense
12 16 20
Other Income / (Expense), net
-0.56 -0.40 -0.94
Income Tax Expense
13 -5.07 14
Net Income / (Loss) Attributable to Noncontrolling Interest
-7.96 2.36 43
Basic Earnings per Share
($100.36) ($10.39) $10.25
Weighted Average Basic Shares Outstanding
650.93M 745.43M 5.53M
Diluted Earnings per Share
($100.36) ($10.39) $9.71
Weighted Average Diluted Shares Outstanding
650.93M 745.43M 5.53M
Weighted Average Basic & Diluted Shares Outstanding
650.93M 745.43M 5.53M

Quarterly Income Statements for Nutex Health

This table shows Nutex Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-412 -15 -5.15 -3.48 -5.54 -32 -0.36 -0.36 -8.79 62
Consolidated Net Income / (Loss)
-423 -11 -6.92 -4.27 -4.52 -28 -0.54 3.01 -7.17 100
Net Income / (Loss) Continuing Operations
-423 -11 -6.92 -4.27 -4.52 -28 -0.54 3.01 -7.17 100
Total Pre-Tax Income
-431 -8.85 -7.83 -5.08 -4.87 -31 -0.15 3.90 -2.58 109
Total Operating Income
-429 -5.78 -4.45 -0.36 -0.82 -26 1.45 5.30 9.66 114
Total Gross Profit
-24 -3.32 4.85 9.65 7.07 13 10 23 22 142
Total Revenue
28 54 56 59 63 70 67 76 79 258
Operating Revenue
28 54 56 59 63 70 67 76 79 258
Total Cost of Revenue
32 61 30 28 32 32 32 32 34 35
Operating Cost of Revenue
32 61 30 28 32 32 32 32 34 35
Total Operating Expenses
426 -1.67 31 31 31 64 34 39 35 109
Selling, General & Admin Expense
23 21 25 27 26 28 29 28 28 89
Depreciation Expense
4.33 3.27 3.99 4.17 4.75 4.68 4.19 4.53 4.97 5.28
Other Operating Expenses / (Income)
0.08 -26 2.12 0.25 0.05 0.64 0.05 -0.06 1.96 15
Total Other Income / (Expense), net
-2.77 -3.07 -3.39 -4.72 -4.04 -4.57 -1.60 -1.39 -12 -5.63
Interest Expense
3.40 2.86 3.14 4.84 4.10 4.24 4.44 5.05 5.38 5.05
Other Income / (Expense), net
0.63 -0.21 -0.25 0.12 0.05 -0.33 2.84 3.66 -6.86 -0.58
Income Tax Expense
-8.54 1.81 -0.91 -0.82 -0.34 -3.00 0.39 0.89 4.58 8.61
Net Income / (Loss) Attributable to Noncontrolling Interest
-11 4.09 -1.77 -0.79 1.02 3.91 -0.18 3.37 1.62 38
Basic Earnings per Share
($0.62) ($0.02) ($0.12) ($0.79) ($1.25) ($0.04) ($0.01) ($0.07) ($1.72) $11.16
Weighted Average Basic Shares Outstanding
649.77M 650.93M 656.56M 661.90M 670.78M 745.43M 49.72M 5.07M 5.44M 5.53M
Diluted Earnings per Share
($0.62) ($0.02) ($0.12) ($0.79) ($1.25) ($0.04) ($0.01) ($0.07) ($1.72) $11.16
Weighted Average Diluted Shares Outstanding
649.77M 650.93M 656.56M 661.90M 670.78M 745.43M 49.72M 5.07M 5.44M 5.53M
Basic & Diluted Earnings per Share
- ($0.02) - - - ($0.04) - - - $11.16
Weighted Average Basic & Diluted Shares Outstanding
649.77M 650.93M 656.56M 661.90M 670.78M 745.43M 49.72M 5.07M 5.44M 5.53M
Cash Dividends to Common per Share
- - - - - - - - - $0.50

Annual Cash Flow Statements for Nutex Health

This table details how cash moves in and out of Nutex Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-1.86 -12 22
Net Cash From Operating Activities
51 1.26 23
Net Cash From Continuing Operating Activities
51 1.71 23
Net Income / (Loss) Continuing Operations
-433 -43 95
Consolidated Net Income / (Loss)
-433 -43 95
Depreciation Expense
13 18 19
Non-Cash Adjustments To Reconcile Net Income
401 35 74
Changes in Operating Assets and Liabilities, net
69 -7.37 -165
Net Cash From Investing Activities
-4.34 -11 -2.67
Net Cash From Continuing Investing Activities
-4.34 -11 -2.67
Purchase of Property, Plant & Equipment
-15 -9.50 -2.30
Acquisitions
13 -0.70 0.00
Other Investing Activities, net
-2.42 -1.04 -0.36
Net Cash From Financing Activities
-48 -2.27 1.09
Net Cash From Continuing Financing Activities
-48 -2.27 1.09
Repayment of Debt
-9.03 -22 -17
Payment of Dividends
-51 -5.21 -6.44
Issuance of Debt
3.44 24 9.28
Issuance of Common Equity
0.00 0.00 9.20
Other Financing Activities, net
8.69 0.30 5.73

Quarterly Cash Flow Statements for Nutex Health

This table details how cash moves in and out of Nutex Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-11 -2.37 -1.42 -0.08 -5.93 -4.82 8.00 11 6.10 -3.33
Net Cash From Operating Activities
-7.30 4.51 1.05 0.01 1.97 -1.78 3.05 13 6.79 0.05
Net Cash From Continuing Operating Activities
-7.30 4.51 1.05 0.01 1.97 -1.32 3.05 13 6.79 0.05
Net Income / (Loss) Continuing Operations
-423 -11 -6.92 -4.27 -4.52 -28 -0.54 3.01 -7.17 100
Consolidated Net Income / (Loss)
-423 -11 -6.92 -4.27 -4.52 -28 -0.54 3.01 -7.17 100
Depreciation Expense
4.33 3.27 3.99 4.17 4.75 4.68 4.19 4.53 4.97 5.28
Non-Cash Adjustments To Reconcile Net Income
399 0.89 2.00 1.22 0.38 31 -2.29 4.11 9.28 63
Changes in Operating Assets and Liabilities, net
13 11 1.97 -1.11 1.37 -9.61 1.70 1.61 -0.29 -168
Net Cash From Investing Activities
-5.89 7.88 -5.42 -3.07 -3.62 0.87 -0.73 -1.27 -0.27 -0.40
Net Cash From Continuing Investing Activities
-5.89 7.88 -5.42 -3.07 -3.62 0.87 -0.73 -1.27 -0.27 -0.40
Purchase of Property, Plant & Equipment
-5.89 7.88 -4.38 -3.07 -2.88 0.83 -0.73 -0.56 -0.62 -0.40
Net Cash From Financing Activities
2.21 -15 2.95 2.98 -4.28 -3.91 5.69 -1.19 -0.42 -2.99
Net Cash From Continuing Financing Activities
2.21 -15 2.95 2.98 -4.28 -3.91 5.69 -1.19 -0.42 -2.99
Repayment of Debt
-1.00 -3.31 -3.15 -7.80 -3.91 -6.70 -5.95 -2.24 -3.18 -5.30
Payment of Dividends
-2.14 -1.26 -1.54 -1.15 -1.65 -0.88 -0.48 -1.38 -1.80 -2.78
Issuance of Debt
5.26 -9.28 7.60 11 1.28 4.02 2.92 2.13 3.10 1.13
Other Financing Activities, net
0.09 -0.90 0.03 0.62 - -0.35 0.00 0.30 1.46 3.96

Annual Balance Sheets for Nutex Health

This table presents Nutex Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
432 398 655
Total Current Assets
98 91 292
Cash & Equivalents
34 22 44
Accounts Receivable
58 63 236
Inventories, net
3.53 3.39 2.85
Prepaid Expenses
1.87 2.68 10.00
Plant, Property, & Equipment, net
82 81 78
Total Noncurrent Assets
252 226 285
Goodwill
17 17 14
Intangible Assets
21 21 16
Noncurrent Deferred & Refundable Income Taxes
- 0.00 7.99
Other Noncurrent Operating Assets
213 188 247
Total Liabilities & Shareholders' Equity
432 398 655
Total Liabilities
311 319 453
Total Current Liabilities
55 58 141
Short-Term Debt
15 14 18
Accounts Payable
28 25 9.61
Accrued Expenses
6.24 13 25
Current Deferred & Payable Income Tax Liabilities
- 0.00 26
Other Current Liabilities
5.92 5.90 62
Total Noncurrent Liabilities
257 261 313
Long-Term Debt
23 26 22
Capital Lease Obligations
204 214 259
Noncurrent Deferred & Payable Income Tax Liabilities
10 5.15 0.00
Other Noncurrent Operating Liabilities
19 15 31
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
120 79 202
Total Preferred & Common Equity
96 61 146
Total Common Equity
96 61 146
Common Stock
459 471 503
Retained Earnings
-363 -409 -357
Noncontrolling Interest
24 18 56

Quarterly Balance Sheets for Nutex Health

This table presents Nutex Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
435 430 436 480 404 422 438
Total Current Assets
108 89 92 90 100 114 120
Cash & Equivalents
37 33 33 27 30 41 47
Accounts Receivable
63 52 52 55 66 65 66
Inventories, net
3.21 3.49 2.45 2.68 2.98 2.76 2.26
Prepaid Expenses
4.38 0.83 4.86 5.65 1.63 5.07 4.28
Plant, Property, & Equipment, net
72 77 83 85 81 79 78
Total Noncurrent Assets
255 264 261 304 223 230 240
Goodwill
17 17 17 18 17 14 14
Intangible Assets
22 21 20 22 20 16 16
Other Noncurrent Operating Assets
216 226 224 265 186 200 211
Total Liabilities & Shareholders' Equity
435 430 436 480 404 422 438
Total Liabilities
302 321 328 375 324 340 359
Total Current Liabilities
44 48 57 67 60 72 68
Short-Term Debt
6.62 13 19 23 12 17 14
Accounts Payable
21 19 20 24 24 24 17
Accrued Expenses
10 10 12 15 18 23 30
Other Current Liabilities
5.59 5.61 5.66 5.73 5.95 7.57 7.32
Total Noncurrent Liabilities
258 273 271 307 264 269 291
Long-Term Debt
25 25 25 19 26 22 27
Capital Lease Obligations
205 221 - 264 213 227 241
Noncurrent Deferred & Payable Income Tax Liabilities
8.83 9.54 8.73 8.49 5.05 2.80 3.40
Other Noncurrent Operating Liabilities
20 17 237 16 20 17 20
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
133 110 108 105 80 82 80
Total Preferred & Common Equity
110 93 93 90 63 63 60
Total Common Equity
110 93 93 90 63 63 60
Common Stock
469 461 465 467 472 473 479
Retained Earnings
-359 -368 -372 -377 -409 -410 -419
Noncontrolling Interest
22 17 16 15 17 19 19

Annual Metrics and Ratios for Nutex Health

This table displays calculated financial ratios and metrics derived from Nutex Health's official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
-33.85% 12.93% 93.80%
EBITDA Growth
-314.90% 96.30% 1,119.47%
EBIT Growth
-331.75% 92.10% 503.07%
NOPAT Growth
-268.12% 92.19% 609.81%
Net Income Growth
-356.78% 89.97% 319.40%
EPS Growth
-356.78% 89.97% 193.46%
Operating Cash Flow Growth
-70.82% -97.52% 1,742.79%
Free Cash Flow Firm Growth
-113.39% 98.08% -473.21%
Invested Capital Growth
5.69% -5.01% 47.10%
Revenue Q/Q Growth
-30.23% 6.88% 64.37%
EBITDA Q/Q Growth
-24.08% -424.77% 1,769.47%
EBIT Q/Q Growth
-23.68% -175.20% 1,344.22%
NOPAT Q/Q Growth
-23.78% -178.53% 1,764.22%
Net Income Q/Q Growth
-22.50% -64.67% 393.97%
EPS Q/Q Growth
-22.50% -64.67% 228.27%
Operating Cash Flow Q/Q Growth
-45.30% -83.33% 8.58%
Free Cash Flow Firm Q/Q Growth
38.40% 90.37% -152.99%
Invested Capital Q/Q Growth
-1.17% -18.92% 45.70%
Profitability Metrics
- - -
Gross Margin
7.03% 14.04% 40.89%
EBITDA Margin
-179.68% -5.89% 30.97%
Operating Margin
-185.41% -12.83% 27.22%
EBIT Margin
-185.67% -12.99% 27.02%
Profit (Net Income) Margin
-197.33% -17.53% 19.85%
Tax Burden Percent
103.12% 89.55% 86.81%
Interest Burden Percent
103.07% 150.72% 84.63%
Effective Tax Rate
0.00% 0.00% 13.19%
Return on Invested Capital (ROIC)
-89.20% -6.96% 29.46%
ROIC Less NNEP Spread (ROIC-NNEP)
-180.00% -16.59% 22.05%
Return on Net Nonoperating Assets (RNNOA)
-188.28% -36.59% 38.35%
Return on Equity (ROE)
-277.48% -43.55% 67.81%
Cash Return on Invested Capital (CROIC)
-94.73% -1.82% -8.66%
Operating Return on Assets (OROA)
-98.54% -7.75% 24.62%
Return on Assets (ROA)
-104.73% -10.46% 18.09%
Return on Common Equity (ROCE)
-187.28% -34.35% 50.15%
Return on Equity Simple (ROE_SIMPLE)
-451.42% -70.66% 65.10%
Net Operating Profit after Tax (NOPAT)
-285 -22 113
NOPAT Margin
-129.79% -8.98% 23.63%
Net Nonoperating Expense Percent (NNEP)
90.80% 9.63% 7.42%
Return On Investment Capital (ROIC_SIMPLE)
-78.59% -6.67% 22.60%
Cost of Revenue to Revenue
56.50% 49.48% 27.67%
SG&A Expenses to Revenue
39.51% 42.80% 36.22%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
228.91% 63.35% 45.11%
Earnings before Interest and Taxes (EBIT)
-407 -32 130
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-394 -15 149
Valuation Ratios
- - -
Price to Book Value (P/BV)
12.88 1.96 1.18
Price to Tangible Book Value (P/TBV)
21.41 5.06 1.47
Price to Revenue (P/Rev)
5.63 0.49 0.36
Price to Earnings (P/E)
0.00 0.00 3.30
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 30.28%
Enterprise Value to Invested Capital (EV/IC)
4.47 1.19 1.06
Enterprise Value to Revenue (EV/Rev)
6.69 1.50 1.01
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 3.26
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 3.73
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 4.27
Enterprise Value to Operating Cash Flow (EV/OCF)
28.98 295.10 20.91
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
2.01 3.22 1.49
Long-Term Debt to Equity
1.88 3.04 1.40
Financial Leverage
1.05 2.21 1.74
Leverage Ratio
2.65 4.16 3.75
Compound Leverage Factor
2.73 6.27 3.17
Debt to Total Capital
66.78% 76.28% 59.77%
Short-Term Debt to Total Capital
4.19% 4.25% 3.58%
Long-Term Debt to Total Capital
62.59% 72.03% 56.19%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
6.76% 5.29% 11.07%
Common Equity to Total Capital
26.47% 18.43% 29.16%
Debt to EBITDA
-0.61 -17.45 2.02
Net Debt to EBITDA
-0.53 -15.94 1.72
Long-Term Debt to EBITDA
-0.58 -16.47 1.90
Debt to NOPAT
-0.85 -11.44 2.64
Net Debt to NOPAT
-0.73 -10.45 2.26
Long-Term Debt to NOPAT
-0.80 -10.80 2.49
Altman Z-Score
-1.28 -0.76 1.13
Noncontrolling Interest Sharing Ratio
32.51% 21.12% 26.05%
Liquidity Ratios
- - -
Current Ratio
1.79 1.56 2.08
Quick Ratio
1.69 1.45 1.99
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-302 -5.81 -33
Operating Cash Flow to CapEx
345.86% 13.23% 1,004.98%
Free Cash Flow to Firm to Interest Expense
-24.20 -0.36 -1.67
Operating Cash Flow to Interest Expense
4.05 0.08 1.16
Operating Cash Flow Less CapEx to Interest Expense
2.88 -0.51 1.05
Efficiency Ratios
- - -
Asset Turnover
0.53 0.60 0.91
Accounts Receivable Turnover
2.53 4.09 3.21
Inventory Turnover
39.04 35.39 42.57
Fixed Asset Turnover
1.87 3.03 6.02
Accounts Payable Turnover
5.48 4.64 7.61
Days Sales Outstanding (DSO)
144.04 89.24 113.63
Days Inventory Outstanding (DIO)
9.35 10.31 8.58
Days Payable Outstanding (DPO)
66.55 78.66 47.95
Cash Conversion Cycle (CCC)
86.83 20.89 74.25
Capital & Investment Metrics
- - -
Invested Capital
328 311 458
Invested Capital Turnover
0.69 0.77 1.25
Increase / (Decrease) in Invested Capital
18 -16 147
Enterprise Value (EV)
1,467 371 484
Market Capitalization
1,235 121 172
Book Value per Share
$0.15 $0.09 $26.92
Tangible Book Value per Share
$0.09 $0.04 $21.50
Total Capital
362 333 502
Total Debt
242 254 300
Total Long-Term Debt
227 240 282
Net Debt
208 232 256
Capital Expenditures (CapEx)
15 9.50 2.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)
24 25 126
Debt-free Net Working Capital (DFNWC)
58 47 170
Net Working Capital (NWC)
43 33 152
Net Nonoperating Expense (NNE)
148 21 18
Net Nonoperating Obligations (NNO)
208 232 256
Total Depreciation and Amortization (D&A)
13 18 19
Debt-free, Cash-free Net Working Capital to Revenue
10.96% 9.98% 26.25%
Debt-free Net Working Capital to Revenue
26.58% 18.86% 35.33%
Net Working Capital to Revenue
19.66% 13.14% 31.59%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($100.50) ($10.50) $10.25
Adjusted Weighted Average Basic Shares Outstanding
4.34M 4.97M 5.53M
Adjusted Diluted Earnings per Share
($100.50) ($10.50) $9.71
Adjusted Weighted Average Diluted Shares Outstanding
4.34M 4.97M 5.53M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
4.34M 4.97M 5.53M
Normalized Net Operating Profit after Tax (NOPAT)
-3.20 -1.06 120
Normalized NOPAT Margin
-1.46% -0.43% 24.91%
Pre Tax Income Margin
-191.36% -19.58% 22.87%
Debt Service Ratios
- - -
EBIT to Interest Expense
-32.60 -1.97 6.51
NOPAT to Interest Expense
-22.79 -1.36 5.69
EBIT Less CapEx to Interest Expense
-33.77 -2.55 6.39
NOPAT Less CapEx to Interest Expense
-23.96 -1.95 5.57
Payout Ratios
- - -
Dividend Payout Ratio
-11.84% -12.01% 6.76%
Augmented Payout Ratio
-11.84% -12.01% 6.76%

Quarterly Metrics and Ratios for Nutex Health

This table displays calculated financial ratios and metrics derived from Nutex Health's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-75.93% -63.88% -28.81% 1.51% 120.89% 29.68% 19.75% 29.12% 25.62% 269.77%
EBITDA Growth
-642.68% -103.69% -102.37% 24.48% 100.94% -701.28% 1,325.01% 243.28% 95.40% 645.70%
EBIT Growth
-661.69% -108.33% -117.47% -1,065.89% 99.82% -341.86% 191.45% 3,848.23% 464.65% 529.22%
NOPAT Growth
-505.44% -105.59% -110.72% 73.70% 99.81% -352.42% 132.61% 1,709.99% 1,276.62% 674.57%
Net Income Growth
-667.71% -115.48% -127.88% 82.22% 98.93% -159.99% 92.16% 170.56% -58.38% 460.75%
EPS Growth
-788.89% -115.48% -127.88% 82.22% 98.93% -159.99% 92.16% 170.56% -37.60% 28,000.00%
Operating Cash Flow Growth
-130.11% -90.29% -97.06% -99.93% 126.96% -139.42% 190.00% 107,538.69% 244.93% 103.01%
Free Cash Flow Firm Growth
-18,760.86% 90.90% -1,036.19% 191.75% 90.56% 91.37% 113.10% -129.71% 244.41% -2,117.77%
Invested Capital Growth
367.29% 5.69% 419.67% -83.74% 15.79% -5.01% -10.40% 156.37% -18.14% 47.10%
Revenue Q/Q Growth
-51.08% 89.20% 4.85% 4.61% 6.45% 11.07% -3.18% 12.79% 3.57% 226.95%
EBITDA Q/Q Growth
-13,520.63% 99.36% 74.55% 667.89% 1.22% -647.79% 138.91% 59.14% -42.39% 1,429.78%
EBIT Q/Q Growth
-1,729,945.58% 98.60% 21.68% 94.91% -221.33% -3,346.96% 116.21% 108.75% -68.74% 3,957.42%
NOPAT Q/Q Growth
-30,998.14% 98.65% 23.08% 91.84% -126.52% -3,083.64% 105.54% 302.65% 65.55% 1,454.63%
Net Income Q/Q Growth
-1,662.26% 97.48% 35.06% 38.36% -6.04% -512.55% 98.04% 654.89% -338.02% 1,495.24%
EPS Q/Q Growth
-1,966.67% 97.48% 35.06% 38.36% -6.04% -512.55% 98.04% 654.89% -2,357.14% 748.84%
Operating Cash Flow Q/Q Growth
-141.34% 161.71% -76.65% -98.83% 15,878.07% -190.24% 271.76% 334.63% -48.80% -99.21%
Free Cash Flow Firm Q/Q Growth
16.69% 96.13% -1,165.63% 324.86% -108.57% 96.46% 2,020.92% -609.74% 141.67% -154.35%
Invested Capital Q/Q Growth
-55.04% -1.17% 2.57% -64.33% 220.23% -18.92% -3.26% 2.07% 2.24% 45.70%
Profitability Metrics
- - - - - - - - - -
Gross Margin
-83.51% -6.18% 8.61% 16.37% 11.27% 18.97% 15.06% 29.65% 27.82% 54.98%
EBITDA Margin
-1,492.23% -5.06% -1.23% 6.67% 6.34% -31.28% 12.57% 17.73% 9.86% 46.16%
Operating Margin
-1,509.70% -10.76% -7.89% -0.62% -1.31% -37.53% 2.15% 6.96% 12.26% 44.33%
EBIT Margin
-1,507.48% -11.15% -8.33% -0.41% -1.22% -38.00% 6.36% 11.78% 3.55% 44.11%
Profit (Net Income) Margin
-1,489.38% -19.84% -12.29% -7.24% -7.21% -39.78% -0.80% 3.96% -9.09% 38.81%
Tax Burden Percent
98.02% 120.39% 88.37% 83.95% 92.97% 90.24% 354.98% 77.10% 277.66% 92.07%
Interest Burden Percent
100.79% 147.77% 166.92% 2,126.30% 633.60% 116.00% -3.56% 43.58% -92.14% 95.55%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.90% 0.00% 7.93%
Return on Invested Capital (ROIC)
-1,649.15% -5.17% -5.41% -0.20% -0.59% -20.35% 1.22% 6.93% 7.18% 50.90%
ROIC Less NNEP Spread (ROIC-NNEP)
-1,774.26% -9.23% -8.90% -4.58% -2.24% -24.63% 0.53% 6.03% 1.76% 48.78%
Return on Net Nonoperating Assets (RNNOA)
-1,687.30% -9.65% -10.64% -1.24% -4.52% -54.33% 1.24% 7.52% 4.89% 84.84%
Return on Equity (ROE)
-3,336.44% -14.83% -16.06% -1.44% -5.12% -74.68% 2.46% 14.45% 12.06% 135.74%
Cash Return on Invested Capital (CROIC)
-243.65% -94.73% -289.14% 72.38% -16.86% -1.82% 5.29% -94.38% 18.00% -8.66%
Operating Return on Assets (OROA)
-1,830.10% -5.92% -6.38% -0.12% -0.62% -22.68% 3.95% 7.57% 2.26% 40.19%
Return on Assets (ROA)
-1,808.12% -10.53% -9.41% -2.19% -3.66% -23.74% -0.50% 2.54% -5.78% 35.36%
Return on Common Equity (ROCE)
-2,980.04% -10.01% -14.47% -1.32% -4.32% -58.91% 2.02% 11.80% 9.82% 100.38%
Return on Equity Simple (ROE_SIMPLE)
-319.72% 0.00% -501.52% -480.20% -29.32% 0.00% -58.78% -47.45% -53.62% 0.00%
Net Operating Profit after Tax (NOPAT)
-300 -4.05 -3.11 -0.25 -0.57 -18 1.01 4.09 6.76 105
NOPAT Margin
-1,056.79% -7.53% -5.52% -0.43% -0.92% -26.27% 1.50% 5.37% 8.58% 40.82%
Net Nonoperating Expense Percent (NNEP)
125.12% 4.05% 3.49% 4.38% 1.65% 4.28% 0.70% 0.91% 5.42% 2.12%
Return On Investment Capital (ROIC_SIMPLE)
- -1.12% - - - -5.49% - - - 20.96%
Cost of Revenue to Revenue
111.06% 113.86% 53.01% 47.73% 51.55% 46.23% 47.92% 42.04% 42.94% 13.46%
SG&A Expenses to Revenue
80.98% 38.37% 44.03% 45.39% 42.05% 40.28% 43.65% 36.35% 35.46% 34.47%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
1,498.65% -3.11% 54.88% 52.88% 49.76% 91.29% 49.93% 50.99% 44.80% 42.21%
Earnings before Interest and Taxes (EBIT)
-428 -5.99 -4.69 -0.24 -0.77 -26 4.29 8.96 2.80 114
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-424 -2.72 -0.69 3.93 3.98 -22 8.48 13 7.77 119
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
8.82 12.88 7.10 2.99 1.49 1.96 1.13 0.47 1.82 1.18
Price to Tangible Book Value (P/TBV)
13.56 21.41 12.00 5.02 2.66 5.06 2.77 0.91 3.58 1.47
Price to Revenue (P/Rev)
3.10 5.63 3.35 1.40 0.58 0.49 0.28 0.11 0.38 0.36
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.30
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 30.28%
Enterprise Value to Invested Capital (EV/IC)
3.60 4.47 2.68 2.54 1.11 1.19 1.03 0.89 1.16 1.06
Enterprise Value to Revenue (EV/Rev)
3.81 6.69 4.59 1.54 1.85 1.50 1.20 0.99 1.25 1.01
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 95.39 0.00 0.00 66.02 45.77 3.26
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.73
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.27
Enterprise Value to Operating Cash Flow (EV/OCF)
12.93 28.98 56.61 0.00 56.81 295.10 95.17 16.63 17.07 20.91
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.98 0.00 0.00 18.36 0.00 5.79 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
1.78 2.01 2.37 0.41 2.92 3.22 3.14 3.25 3.53 1.49
Long-Term Debt to Equity
1.73 1.88 2.25 0.23 2.70 3.04 2.99 3.04 3.36 1.40
Financial Leverage
0.95 1.05 1.20 0.27 2.02 2.21 2.36 1.25 2.78 1.74
Leverage Ratio
2.51 2.65 2.81 1.94 3.85 4.16 4.40 4.51 4.97 3.75
Compound Leverage Factor
2.53 3.92 4.69 41.23 24.39 4.83 -0.16 1.97 -4.58 3.58
Debt to Total Capital
64.03% 66.78% 70.33% 29.14% 74.48% 76.28% 75.85% 76.46% 77.92% 59.77%
Short-Term Debt to Total Capital
1.80% 4.19% 3.56% 12.70% 5.60% 4.25% 3.67% 4.92% 3.84% 3.58%
Long-Term Debt to Total Capital
62.23% 62.59% 66.77% 16.44% 68.88% 72.03% 72.18% 71.54% 74.08% 56.19%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
5.98% 6.76% 4.58% 10.22% 3.64% 5.29% 5.13% 5.54% 5.35% 11.07%
Common Equity to Total Capital
29.99% 26.47% 25.09% 60.64% 21.88% 18.43% 19.02% 18.01% 16.72% 29.16%
Debt to EBITDA
-0.74 -0.61 -0.61 -0.11 68.18 -17.45 -46.50 64.08 35.42 2.02
Net Debt to EBITDA
-0.63 -0.53 -0.53 -0.03 62.20 -15.94 -40.95 54.27 29.52 1.72
Long-Term Debt to EBITDA
-0.72 -0.58 -0.58 -0.06 63.05 -16.47 -44.25 59.96 33.67 1.90
Debt to NOPAT
-1.03 -0.85 -0.84 -0.14 -38.33 -11.44 -13.87 -18.82 -41.33 2.64
Net Debt to NOPAT
-0.87 -0.73 -0.74 -0.04 -34.97 -10.45 -12.22 -15.94 -34.45 2.26
Long-Term Debt to NOPAT
-1.00 -0.80 -0.80 -0.08 -35.45 -10.80 -13.20 -17.61 -39.29 2.49
Altman Z-Score
-1.57 1.78 0.57 -0.14 -0.35 -0.71 -0.49 -0.46 -0.32 1.05
Noncontrolling Interest Sharing Ratio
10.68% 32.51% 9.91% 8.35% 15.59% 21.12% 17.89% 18.34% 18.58% 26.05%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.45 1.79 1.85 1.60 1.34 1.56 1.68 1.59 1.77 2.08
Quick Ratio
2.28 1.69 1.76 1.48 1.21 1.45 1.60 1.48 1.68 1.99
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-561 -22 -275 618 -53 -1.87 36 -184 76 -42
Operating Cash Flow to CapEx
-123.96% 0.00% 24.04% 0.40% 68.45% 0.00% 416.03% 2,375.63% 1,100.12% 13.53%
Free Cash Flow to Firm to Interest Expense
-164.84 -7.58 -87.49 127.55 -12.92 -0.44 8.10 -36.31 14.21 -8.23
Operating Cash Flow to Interest Expense
-2.15 1.57 0.34 0.00 0.48 -0.42 0.69 2.62 1.26 0.01
Operating Cash Flow Less CapEx to Interest Expense
-3.88 4.33 -1.06 -0.63 -0.22 -0.22 0.52 2.51 1.15 -0.07
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
1.21 0.53 0.77 0.30 0.51 0.60 0.62 0.64 0.64 0.91
Accounts Receivable Turnover
9.86 2.53 7.33 2.67 3.93 4.09 4.41 4.71 4.82 3.21
Inventory Turnover
0.00 39.04 0.00 56.25 51.39 35.39 38.69 49.46 52.75 42.57
Fixed Asset Turnover
8.70 1.87 5.10 2.62 2.94 3.03 3.28 3.41 3.57 6.02
Accounts Payable Turnover
12.87 5.48 13.12 6.86 6.72 4.64 5.81 5.87 6.45 7.61
Days Sales Outstanding (DSO)
37.02 144.04 49.82 136.90 92.96 89.24 82.70 77.55 75.65 113.63
Days Inventory Outstanding (DIO)
0.00 9.35 0.00 6.49 7.10 10.31 9.43 7.38 6.92 8.58
Days Payable Outstanding (DPO)
28.37 66.55 27.81 53.18 54.33 78.66 62.85 62.15 56.57 47.95
Cash Conversion Cycle (CCC)
8.66 86.83 22.01 90.21 45.73 20.89 29.28 22.78 26.00 74.25
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
332 328 336 120 384 311 301 308 314 458
Invested Capital Turnover
1.56 0.69 0.98 0.46 0.65 0.77 0.81 1.29 0.84 1.25
Increase / (Decrease) in Invested Capital
261 18 272 -618 52 -16 -35 188 -70 147
Enterprise Value (EV)
1,196 1,467 901 304 428 371 310 274 364 484
Market Capitalization
975 1,235 657 277 134 121 71 30 110 172
Book Value per Share
$0.17 $0.15 $0.14 $0.14 $0.14 $0.09 $0.08 $1.26 $11.93 $26.92
Tangible Book Value per Share
$0.11 $0.09 $0.08 $0.08 $0.08 $0.04 $0.03 $0.66 $6.05 $21.50
Total Capital
368 362 369 153 411 333 331 348 361 502
Total Debt
236 242 260 44 306 254 251 266 282 300
Total Long-Term Debt
229 227 247 25 283 240 239 249 268 282
Net Debt
199 208 227 12 279 232 221 226 235 256
Capital Expenditures (CapEx)
5.89 -7.88 4.38 3.07 2.88 -0.83 0.73 0.56 0.62 0.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)
34 24 21 21 19 25 23 19 19 126
Debt-free Net Working Capital (DFNWC)
70 58 54 54 46 47 53 59 66 170
Net Working Capital (NWC)
64 43 41 35 23 33 40 42 52 152
Net Nonoperating Expense (NNE)
123 6.61 3.81 4.01 3.95 9.41 1.56 1.08 14 5.18
Net Nonoperating Obligations (NNO)
199 208 227 12 279 232 221 226 235 256
Total Depreciation and Amortization (D&A)
4.33 3.27 4.00 4.17 4.75 4.68 4.19 4.53 4.97 5.28
Debt-free, Cash-free Net Working Capital to Revenue
10.73% 10.96% 10.73% 10.78% 8.10% 9.98% 8.74% 6.72% 6.58% 26.25%
Debt-free Net Working Capital to Revenue
22.38% 26.58% 27.44% 27.37% 19.68% 18.86% 20.34% 21.51% 22.64% 35.33%
Net Working Capital to Revenue
20.27% 19.66% 20.76% 17.55% 9.75% 13.14% 15.64% 15.30% 17.89% 31.59%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($97.50) ($3.00) ($1.50) ($1.50) ($1.50) ($6.00) ($0.10) ($0.07) ($1.72) $11.16
Adjusted Weighted Average Basic Shares Outstanding
4.33M 4.34M 4.38M 4.41M 4.47M 4.97M 4.97M 5.07M 5.44M 5.53M
Adjusted Diluted Earnings per Share
($97.50) ($3.00) ($1.50) ($1.50) ($1.50) ($6.00) ($0.10) ($0.07) ($1.72) $11.16
Adjusted Weighted Average Diluted Shares Outstanding
4.33M 4.34M 4.38M 4.41M 4.47M 4.97M 4.97M 5.07M 5.44M 5.53M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($3.00) $0.00 $0.00 $0.00 ($6.00) $0.00 $0.00 $0.00 $11.16
Adjusted Weighted Average Basic & Diluted Shares Outstanding
4.33M 4.34M 4.38M 4.41M 4.47M 4.97M 4.97M 5.07M 5.44M 5.53M
Normalized Net Operating Profit after Tax (NOPAT)
-21 -4.05 -3.11 -0.25 -0.54 -18 1.01 9.23 7.06 105
Normalized NOPAT Margin
-75.30% -7.53% -5.52% -0.43% -0.87% -26.27% 1.50% 12.13% 8.96% 40.82%
Pre Tax Income Margin
-1,519.46% -16.48% -13.91% -8.62% -7.76% -44.08% -0.23% 5.13% -3.27% 42.15%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-125.80 -2.09 -1.49 -0.05 -0.19 -6.25 0.97 1.77 0.52 22.49
NOPAT to Interest Expense
-88.19 -1.41 -0.99 -0.05 -0.14 -4.32 0.23 0.81 1.26 20.81
EBIT Less CapEx to Interest Expense
-127.53 0.66 -2.89 -0.68 -0.89 -6.05 0.80 1.66 0.41 22.41
NOPAT Less CapEx to Interest Expense
-89.92 1.34 -2.38 -0.69 -0.84 -4.13 0.06 0.70 1.14 20.74
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
-26.22% -11.84% -4.29% -1.37% -21.21% -12.01% -11.23% -14.75% -14.00% 6.76%
Augmented Payout Ratio
-26.22% -11.84% -4.29% -1.37% -21.21% -12.01% -11.23% -14.75% -14.00% 6.76%

Frequently Asked Questions About Nutex Health's Financials

When does Nutex Health's financial year end?

According to the most recent income statement we have on file, Nutex Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Nutex Health's net income changed over the last 2 years?

Nutex Health's net income appears to be on a downward trend, with a most recent value of $95.27 million in 2024, falling from -$432.74 million in 2022. The previous period was -$43.42 million in 2023.

What is Nutex Health's operating income?
Nutex Health's total operating income in 2024 was $130.62 million, based on the following breakdown:
  • Total Gross Profit: $196.26 million
  • Total Operating Expenses: $216.52 million
How has Nutex Health revenue changed over the last 2 years?

Over the last 2 years, Nutex Health's total revenue changed from $219.29 million in 2022 to $479.95 million in 2024, a change of 118.9%.

How much debt does Nutex Health have?

Nutex Health's total liabilities were at $453.43 million at the end of 2024, a 42.1% increase from 2023, and a 45.6% increase since 2022.

How much cash does Nutex Health have?

In the past 2 years, Nutex Health's cash and equivalents has ranged from $22.00 million in 2023 to $43.58 million in 2024, and is currently $43.58 million as of their latest financial filing in 2024.

How has Nutex Health's book value per share changed over the last 2 years?

Over the last 2 years, Nutex Health's book value per share changed from 0.15 in 2022 to 26.92 in 2024, a change of 18,148.4%.



This page (NASDAQ:NUTX) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners